Bone Marrow & Stem Cell Transplant

Jeremy S. Abramson, MD, discusses the significant 2-year follow-up results from the phase 3 STARGLO trial in DLBCL.

Jamie Jacobs, PhD, provides background on a digital intervention for caregivers of patients undergoing bone marrow transplant.

Tabelecleucel shows promising efficacy in treating EBV-positive PTLD, offering hope for patients resistant to previous therapies.

The safety and efficacy outcomes of a total of 3 CD19-directed CAR T-cell therapies were confirmed with other real-world data with CAR T-cell therapy in patients with B-cell malignancies.

Jamie Jacobs, PhD, discusses a study assessing the BMT-CARE App, a self-guided digital intervention for caregivers of patients undergoing stem cell transplant.

Alfred L. Garfall, MD, provided a deep dive into the phase 2 BMT CTN 1902 trial of ide-cel in multiple myeloma after transplant.

A phase 3 trial did not support a transplant-based approach for patients who already achieved MRD negativity or a tandem transplant approach for those who did not achieve prior MRD negativity.

Transplantation improves survival after cladribine-based therapy for patients with relapsed/refractory acute myeloid leukemia, per phase 2 trial findings.

The resubmitted biologics license application for narsoplimab in transplant-associated thrombotic microangiopathy has been accepted by the FDA.

With the clinical hold on the tab-cel application lifted, phase 2 and 3 trials of the T-cell immunotherapy in patients with PTLD may resume.

Jeff Auletta, MD, discussed the ACCESS trial and explained that mismatched unrelated donor transplants can be a viable option.

During a live event, Catherine J. Lee, MD, MS, discussed the mechanism of action of approved therapies for chronic graft-vs-host disease and reasons to select one over others.

The impact of physical and nutritional rehabilitation post bone marrow transplant in patients with hematologic malignancies will be determined in the REBOOT trial.

During a live event, Catherine J. Lee, MD, MS, discussed the efficacy and safety results of various trials of approved agents for treating chronic graft-vs-host disease.

During a live event, Catherine J. Lee, MD, MS, discussed the results of the AGAVE-201 trial.

Orca-T improved 1-year survival without severe graft-vs-host disease compared with standard transplant in the Precision-T study.

Anthony Stein, MD, assessed total marrow and lymphoid irradiation with post-transplant cyclophosphamide in patients with acute myeloid leukemia.

In this episode of Targeted Talks, Alfred L. Garfall, discusses the phase 2 BMT CTN 1902 trial of idecabtagene vicleucel in patients with multiple myeloma.

Two denosumab biosimilars have gained FDA approvals across multiple indications.

Jeff Auletta, MD, discusses his key takeaways from the 2025 Transplant and Cellular Therapy Meetings.

Colton Ladbury, MD, discusses radiation therapy for hematologic malignancies, total marrow irradiation, and findings that were presented during the American Society for Radiation Oncology Annual Meeting.

A study found a 94% 6-month survival rate after tandem autologous stem cell transplant for high-risk neuroblastoma, but serious complications reduced survival.

The FDA granted Regenerative Medicine Advanced Therapy designation to NXC-201 for the treatment of relapsed/refractory light chain amyloidosis.

Orca-T improved overall survival vs post-transplant cyclophosphamide in a retrospective analysis.

Orca-T with reduced-intensity stem cell transplantation was a safe, feasible alternative to conventional transplant in blood cancers, per phase 1 data.